Literature DB >> 10729660

Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.

Y C Chen1, S C Chang, C C Shih, C C Hung, K T Luhbd, Y S Pan, W C Hsieh.   

Abstract

One hundred years after introduction of the Eucalyptus tree to Taiwan, a predominantly subtropical island, we analyzed clinical and microbiological data of 59 patients with Cryptococcus neoformans infection hospitalized at National Taiwan University Hospital during 1982 to 1997. There were 38 (64.4%) cases of cryptococcosis caused by the var. neoformans and 21 (35.6%) caused by the var. gattii. Thirty-three patients (55.9%) had impaired T cell function, which included 12 patients with acquired immunodeficiency syndrome (AIDS). Eleven of the 12 patients with AIDS were diagnosed after 1995, and 11 cases were caused by var. neoformans. Minimum inhibitory concentrations (MICs) determined by the NCCLS broth microdilution method using antibiotic medium 3 improved the discrimination of in vitro susceptibility against amphotericin B and demonstrated that var. gattii isolates were less susceptible (geometric means 0.25 microg/ml versus 0.64 microg/ml, P < 0.001). In addition, a higher proportion of var. gattii were less susceptible to flucytosine as compared with var. neoformans (35.0% versus 64.9%, P = 0.030). There was no seasonal clustering for isolation of var. neoformans, though infections caused by var. gattii peaked in July and August. Compared with the first study of cryptococcosis (1957-1972) at NTUH, this study demonstrated the increase in immunocompromised and elderly patients, as well as a higher proportion of Cryptococcus isolated from blood or bone marrow. Facing the increasing adaptive plantation of Eucalyptus in Taiwan, the importance of field study regarding the role of Eucalyptus plantations in Taiwan and occurrence of cryptococcosis in human beings cannot be over-emphasized.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729660     DOI: 10.1016/s0732-8893(99)00137-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  20 in total

1.  Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

2.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

3.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Primary cutaneous Cryptococcus neoformans serotype D presenting as painful ulcer and nodules on elbow of an immunocompetent patient.

Authors:  A Murad; A Murphy
Journal:  Ir J Med Sci       Date:  2014-09-27       Impact factor: 1.568

Review 5.  Intra-abdominal cryptococcosis by Cryptococcus gattii: case report and review.

Authors:  Bruno S Araújo; Monica Bay; Roberta Reichert; Luciano Z Goldani
Journal:  Mycopathologia       Date:  2012-01-14       Impact factor: 2.574

6.  Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

Authors:  Naureen Iqbal; Emilio E DeBess; Ron Wohrle; Ben Sun; Randall J Nett; Angela M Ahlquist; Tom Chiller; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.

Authors:  George R Thompson; Nathan P Wiederhold; Annette W Fothergill; Ana C Vallor; Brian L Wickes; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 8.  Spread of Cryptococcus gattii into Pacific Northwest region of the United States.

Authors:  Kausik Datta; Karen H Bartlett; Rebecca Baer; Edmond Byrnes; Eleni Galanis; Joseph Heitman; Linda Hoang; Mira J Leslie; Laura MacDougall; Shelley S Magill; Muhammad G Morshed; Kieren A Marr
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

9.  A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.

Authors:  Tran Th Chau; Nguyen H Mai; Nguyen H Phu; Ho D Nghia; Ly V Chuong; Dinh X Sinh; Van A Duong; Pham T Diep; James I Campbell; Stephen Baker; Tran T Hien; David G Lalloo; Jeremy J Farrar; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2010-07-09       Impact factor: 3.090

10.  Molecular identification of Cryptococcus neoformans serotypes.

Authors:  A Enache-Angoulvant; J Chandenier; F Symoens; P Lacube; J Bolognini; C Douchet; J L Poirot; C Hennequin
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.